Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Tytuł:
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
Autorzy:
Zhiling Yan
Huanxin Zhang
Jiang Cao
Cheng Zhang
Hui Liu
Hongming Huang
Hai Cheng
Jianlin Qiao
Ying Wang
Yan Wang
Lei Gao
Ming Shi
Wei Sang
Feng Zhu
Depeng Li
Haiying Sun
Qingyun Wu
Yuekun Qi
Hujun Li
Xiangmin Wang
Zhenyu Li
Hong Liu
Junnian Zheng
Wenbin Qian
Xi Zhang
Kailin Xu
Temat:
cytokine release syndrome
chimeric antigen receptor T cell
acute lymphocyte leukemia
lymphoma
multiple myeloma
Immunologic diseases. Allergy
RC581-607
Źródło:
Frontiers in Immunology, Vol 12 (2021)
Wydawca:
Frontiers Media S.A., 2021.
Rok publikacji:
2021
Kolekcja:
LCC:Immunologic diseases. Allergy
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1664-3224
Relacje:
https://www.frontiersin.org/articles/10.3389/fimmu.2021.611366/full; https://doaj.org/toc/1664-3224
DOI:
10.3389/fimmu.2021.611366
Dostęp URL:
https://doaj.org/article/d7a421202ef341b18e93604228fa4585  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.7a421202ef341b18e93604228fa4585
Czasopismo naukowe
Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understanding of the characteristics and related risk factors of CRS is important for effective management. A total of 142 patients with relapsed or refractory acute lymphocyte leukemia (ALL), lymphoma, or multiple myeloma (MM) received lymphodepletion chemotherapy followed by infusion of CAR-T cells. The characteristics of CRS at different time points after treatment were monitored and risk factors were analyzed. The incidence of CRS for ALL, lymphoma, and multiple myeloma were 82%, 90%, and 90% respectively. Fever was observed on a median of day 3 for ALL, day 1 for lymphoma, and day 8.5 for MM after CAR-T cell infusion, and the duration was different between grade 1–2 CRS and grade 3–5 CRS. Disease types, peak concentration of IL-6, and CRP were associated with CRS. For patients with ALL, numbers of lymphoblast in bone marrow before lymphodepletion, peak concentration of IL-6, and CRP were independent risk factors of CRS. Clinical stage of lymphoma patients and high tumor burden in marrow of MM patients were independent risk factors of CRS. In conclusion, the characteristics and risk factors of CRS in different B-cell hematological tumors are different and should be managed individually during CAR-T cell therapy.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies